OpGen (OPGN) AI Stock Analysis

• Market Cap: $179.27M
• Dividend Yield: N/A
• Average Volume (3M): 1.29K
• Price to Earnings (P/E): 44.2
• Beta (1Y): -10844.40
• Revenue Growth: 610.97%
• EPS Growth: N/A
• Country: US
• Employees: 85
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): N/A
• Shares Outstanding: 10,071,286
• 10 Day Avg. Volume: 0
• 30 Day Avg. Volume: 1,287
• PEG Ratio: >-0.01
• Price to Book (P/B): 0.38
• Price to Sales (P/S): 0.53
• P/FCF Ratio: -0.57
• Enterprise Value/Market Cap: <0.01
• Enterprise Value/Revenue: 0.16
• Enterprise Value/Gross Profit: 0.17
• Enterprise Value/Ebitda: 0.21
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 40 Underperform
• Price Target: ―

OpGen's overall stock score is low due to significant financial challenges, including declining revenues, negative profitability, and reliance on external financing. Technical indicators suggest a bearish trend with potential overbought conditions, and valuation metrics highlight unprofitability. These factors collectively indicate substantial risk and uncertainty in the company's near-term performance.

Positive Factors

Revenue Growth

A 52% revenue growth rate indicates strong demand for OpGen's diagnostic products, suggesting robust market positioning and potential for sustained growth.

Leadership Changes

The appointment of experienced leaders in key roles can enhance strategic execution and operational efficiency, supporting long-term business objectives.

Product Demand

Addressing antimicrobial resistance positions OpGen as a critical player in healthcare, driving sustained demand for its diagnostic solutions.

Negative Factors

Financial Sustainability

Reliance on external funding and high leverage can threaten financial stability, limiting the company's ability to invest in growth and innovation.

Cash Flow Challenges

Persistent negative cash flow reflects operational inefficiencies and may constrain the company's ability to fund operations and strategic initiatives.

Profitability Issues

Ongoing unprofitability and negative margins highlight cost management issues, impacting long-term viability and competitive positioning.

OpGen Business Overview & Revenue Model

Company Description

OpGen, Inc., a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits. The company's products also comprise ARES Technology Platform, including ARES reference database on antimicrobial resistance using next generation sequencing technology and artificial intelligence powered bioinformatics solutions for antibiotic response prediction; and Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers. The company utilizes molecular diagnostics and informatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections to enhance patient outcomes, and to decrease the spread of infections caused by multidrug-resistant microorganisms. OpGen, Inc. has a collaboration with the New York State Department of Health and ILÚM Health Solutions, LLC to develop a research program to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is headquartered in Rockville, Maryland.

How the Company Makes Money

OpGen generates revenue primarily through the sale of its diagnostic products and services. The company's revenue model is based on selling its molecular diagnostic tests, such as the Acuitas AMR Gene Panel and the Unyvero platform, to hospitals, laboratories, and healthcare providers. Additionally, OpGen earns income from service agreements, where it provides testing services using its proprietary technology. Key partnerships with healthcare institutions and collaborations with other biotech firms enhance its market reach and contribute to its earnings. The company's focus on addressing challenges related to antimicrobial resistance creates a demand for its products, further driving its revenue streams.

OpGen Financial Statement Overview

Summary

OpGen is struggling financially with declining revenues, consistent losses, and cash flow challenges. While there are some signs of improvement in equity, high leverage and dependency on external financing raise concerns about financial sustainability and risk management. Efforts to improve operational efficiency and cost management are crucial for future stability.

Income Statement

OpGen experienced a significant decline in revenue from 2023 to 2024 TTM, with a negative gross profit margin indicating cost challenges. The net profit margin is also negative due to consistent losses, reflecting ongoing unprofitability. EBIT and EBITDA margins are similarly negative, highlighting operational inefficiencies and high expenses relative to revenue.

Balance Sheet

The balance sheet shows improvement in stockholders' equity moving from negative to positive in 2024 TTM, improving its financial stability. However, the company still faces high leverage with a significant amount of total debt relative to equity, posing risks of financial instability.

Cash Flow

Cash flow remains a concern with negative operating and free cash flow, indicating cash outflows that surpass cash inflows from operations. Although there is substantial financing inflow, reliance on external funding increases financial risk and sustainability concerns.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	9.00M	5.20M	3.42M	2.61M	4.31M	4.21M
Gross Profit	8.90M	5.16M	-90.69K	-817.00K	1.46M	365.95K
EBITDA	7.22M	12.35M	-29.51M	-32.38M	-27.25M	-20.34M
Net Income	6.84M	11.99M	-32.67M	-37.28M	-34.81M	-26.21M
Balance Sheet
Total Assets	12.64M	9.86M	1.88M	25.83M	71.67M	49.75M
Cash, Cash Equivalents and Short-Term Investments	414.21K	1.31M	1.15M	7.44M	36.08M	13.36M
Total Debt	1.89M	2.11M	13.04M	14.84M	25.18M	22.85M
Total Liabilities	2.48M	2.48M	13.44M	18.25M	30.45M	28.56M
Stockholders Equity	10.16M	7.38M	-11.56M	7.58M	41.22M	21.19M
Cash Flow
Free Cash Flow	-1.21M	-4.87M	-15.12M	-21.04M	-23.46M	-23.53M
Operating Cash Flow	-1.21M	-4.87M	-14.32M	-20.45M	-21.48M	-23.40M
Investing Cash Flow	0.00	0.00	-800.41K	-590.77K	-1.98M	-1.06M
Financing Cash Flow	-98.31K	5.03M	8.37M	-6.74M	47.45M	34.09M

OpGen Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 17.69
• 50DMA: Positive
• 100DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OPGN, the sentiment is Positive. The current price of 17.69 is above the 20-day moving average (MA) of 14.72, above the 50-day MA of 9.38, and equal to the 200-day MA of ―, indicating a neutral trend. The MACD of 2.42 indicates Negative momentum. The RSI at 76.80 is Negative, neither overbought nor oversold. The STOCH value of 74.95 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for OPGN.

OpGen Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BNR	57 Neutral	$250.86M	-14.58	-19.87%	―	5.44%	72.17%
PRPO	56 Neutral	$43.40M	-31.22	-9.76%	―	30.95%	59.67%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BDSX	50 Neutral	$43.44M	-1.51	-302.55%	―	22.29%	31.93%
VNRX	49 Neutral	$40.89M	-1.50	―	―	14.48%	36.83%
OPGN	40 Underperform	$179.27M	44.25	-331.94%	―	610.97%	―
BNGO	40 Underperform	$16.08M	-0.10	-78.22%	―	-13.84%	88.80%

OpGen Corporate Events

OpGen amends financing deal and announces president’s resignation

On December 17, 2025, OpGen, Inc. further amended its existing financing arrangement with AEI Capital Ltd. by signing a Supplemental Letter that extends the company’s ability to sell up to $9.0 million of its common stock to the investor under a previously established Securities Purchase Agreement through December 31, 2026, in private, unregistered transactions relying on exemptions under U.S. securities laws. On December 18, 2025, the company also disclosed that President David Lazar had submitted his resignation, effective January 8, 2026, and stated that his departure was not due to any disagreement over the company’s operations, policies, or practices.

OpGen Appoints New CEO Christian-Laurent Bonte

On December 1, 2025, OpGen announced the resignation of John Tan Honjian from his role as Chief Executive Officer, although he will remain as Chairman of the Board. Christian-Laurent Bonte was appointed as the new CEO, bringing extensive investment banking experience from his previous roles in Hong Kong and Singapore. His compensation package includes a base salary, guaranteed bonus, performance bonus, and stock grants, reflecting the company’s strategic focus on leveraging his expertise to enhance its market position.